From GlobeNewswire:

Iovance Biotherapeutics, Inc. approved the grant of inducement stock options for six employees, covering an aggregate of 51,375 shares of the company’s common stock. The awards were granted under the company’s 2021 Inducement Plan and each stock option has an exercise price of $7.94. The options vest over a three-year period, subject to continued employment with the company. The company specializes in developing novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, with a promising late-stage TIL product candidate for metastatic melanoma. The company aims to be a global leader in TIL therapies and is committed to continuous innovation in cell therapy.



Read more: Iovance Biotherapeutics Reports Inducement Grants under